The Food and Drug Administration has posted a warning regarding misleading statements made by biotech billionaire Dr. Patrick Soon-Shiong about his company's bladder cancer drug Anktiva.

The FDA's action represents regulatory scrutiny of claims made by Soon-Shiong, who heads the biotechnology company that developed Anktiva for bladder cancer treatment. The agency determined that certain statements about the drug's capabilities or effectiveness did not align with approved labeling or clinical evidence.

Soon-Shiong, a prominent figure in biotechnology and medical research, has built significant wealth through various healthcare ventures. His company's bladder cancer drug Anktiva has been subject to regulatory review as part of the standard drug approval and monitoring process.

The FDA regularly monitors promotional materials and public statements made by pharmaceutical and biotechnology companies to ensure they accurately represent approved treatments. When the agency identifies potentially misleading claims, it issues warnings to protect consumers and healthcare providers from inaccurate information.

The warning serves as a reminder to biotechnology executives and companies about the importance of adhering to FDA guidelines when discussing their products publicly. Misleading statements about medical treatments can potentially influence patient care decisions and must meet strict regulatory standards for accuracy.